TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19364933

Group type: EXPERIMENTAL
Intervention: Interferon beta-daclizumab combination therapy (months 0-5.5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daclizumab monotherapy (months 6.5-15.5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Interferon beta monotherapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg) as an intravenous infusion every 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pilot biomarkers (increase in CD56bright natural killer cells and decrease in CD8+ T cells)
Number of subjects: 15
Study: 19364977

Group type: EXPERIMENTAL
Intervention: Systolic BP categories (<120, 120 to 129, 130 to 139, 140 to 159, and >=160 mm Hg)
Number of subjects: 34221

Group type: EXPERIMENTAL
Intervention: Diastolic BP categories (<65, 65 to 74, 75 to 84, 85 to 89, 90 to 94, and >=95 mm Hg)
Number of subjects: 34221

Group type: EXPERIMENTAL
Intervention: Systolic BP categories (updated models)
Number of subjects: 34221

Group type: EXPERIMENTAL
Intervention: Diastolic BP categories (updated models)
Number of subjects: 34221
Study: 19365012

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab, 1.0% for 3 weeks
Number of subjects: 10
Study: 19365014

Group type: EXPERIMENTAL
Intervention: 16-electrode epiretinal prosthesis
Number of subjects: 1

Group type: COMPARATOR
Intervention: System off (control)
Number of subjects: 1
Study: 19366446

Group type: EXPERIMENTAL
Intervention: Compassionate treatment with tumor-specific frequencies
Number of subjects: 163
Study: 19366777

Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Autologous nonmyeloablative HSCT
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 23
Study: 19369238

Group type: EXPERIMENTAL
Intervention: Flickering light stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sublingual application of 0.8 mg GTN
Number of subjects: 40
Study: 19369372

Group type: EXPERIMENTAL
Intervention: Golden Rice (65-98 g servings containing 0.99-1.53 mg beta-carotene) with 10 g butter
Number of subjects: 5

Group type: COMPARATOR
Intervention: [13C10]retinyl acetate reference dose (0.4-1.0 mg) in oil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Golden Rice beta-carotene
Number of subjects: 5
Study: 19371392

Group type: COMPARATOR
Intervention: Bortezomib 1.3 mg/m² (i.v. bolus days 1, 4, 8, 11) for up to eight 21-day cycles (C)
Number of subjects: 111
Study: 19375217

Group type: EXPERIMENTAL
Intervention: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally for 1 week, 1 month, or until disease progression.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally.
Number of subjects: 12
Study: 19376309

Group type: EXPERIMENTAL
Intervention: CABG plus SVR
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 1000
Study: 19376495

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg) administered as 3 consecutive monthly injections, followed by a variable-dosing regimen based on OCT criteria.
Number of subjects: 40
Study: 19376616

Group type: EXPERIMENTAL
Intervention: Wearable hemodialysis device for 4 to 8 hours
Number of subjects: 8
Study: 19377166

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 75

Group type: COMPARATOR
Intervention: non-VR group
Number of subjects: 75

Group type: COMPARATOR
Intervention: waiting list (WL) group
Number of subjects: 75
Study: 19377385

Group type: EXPERIMENTAL
Intervention: Triple therapy of OAC, aspirin and clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 19380364

Group type: EXPERIMENTAL
Intervention: Robot-assisted resection of indicated tumors
Number of subjects: 36
Study: 19380866

Group type: EXPERIMENTAL
Intervention: Bortezomib plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upfront chemotherapy
Number of subjects: 0
Study: 19381280

Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI identified by DE-CMR
Number of subjects: 185

Group type: COMPARATOR
Intervention: Q-wave UMI identified by electrocardiography
Number of subjects: 185

Group type: COMPARATOR
Intervention: Patients without MI
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI patients
Number of subjects: 185

Group type: COMPARATOR
Intervention: Q-wave UMI patients
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Non-Q-wave UMI
Number of subjects: 185
Study: 19383032

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg b.i.d.)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg q.d.)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 598

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 598
Study: 19386738

Group type: EXPERIMENTAL
Intervention: Iron excretion in men
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Iron excretion in menstruating women
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Iron excretion in postmenopausal women
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Iron excretion in menstruating women (excluding hormonal contraceptive users)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Body iron change in menstruating women
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Body iron change in men
Number of subjects: 53
Study: 19386746

Group type: EXPERIMENTAL
Intervention: Measured metabolizable energy intake (MEI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Food records
Number of subjects: 34
Study: 19386937

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19387077

Group type: EXPERIMENTAL
Intervention: DMXAA (3000 mg x m(-2))
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DMXAA (IV infusion for 20 minutes)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DMXAA (IV infusion for 6 weeks, one dose per week)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DMXAA (various doses)
Number of subjects: 21
Study: 19387313

Group type: EXPERIMENTAL
Intervention: Inpatient neurocognitive testing
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Initial in-hospital testing
Number of subjects: 116
Study: 19388836

Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI >or= 40.0 kg/m(2))
Number of subjects: 2037
Study: 19389332

Group type: EXPERIMENTAL
Intervention: Lithium administration for 4 weeks
Number of subjects: 28
Study: 19394037

Group type: EXPERIMENTAL
Intervention: High-dose extended-release methylphenidate (OROS MPH) up to 1.5 mg/kg/d
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High-dose extended-release methylphenidate (OROS MPH)
Number of subjects: 114
Study: 19394543

Group type: EXPERIMENTAL
Intervention: Endovascular repair of TAAA using custom designed multi-branched stent-grafts
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Endovascular repair of TAAA
Number of subjects: 38
Study: 19394894

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg once daily
Number of subjects: 126
Study: 19395440

Group type: EXPERIMENTAL
Intervention: Fasting direct LDL-C
Number of subjects: 27331

Group type: EXPERIMENTAL
Intervention: Fasting Friedewald LDL-C
Number of subjects: 27331

Group type: EXPERIMENTAL
Intervention: Nonfasting direct LDL-C
Number of subjects: 27331

Group type: EXPERIMENTAL
Intervention: Fasting LDL-C measurements
Number of subjects: 27331
Study: 19398716

Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride (TLK199 tablets) at dose levels of 200 to 6000 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride (TLK199 tablets)
Number of subjects: 45
Study: 19399156

Group type: EXPERIMENTAL
Intervention: RDT-aided malaria diagnosis
Number of subjects: 1887

Group type: COMPARATOR
Intervention: Symptom-based clinical diagnosis (CD) alone
Number of subjects: 1887
Study: 19399550

Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding (liquid diet on POD 2, soft diet on POD 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional diet schedule (control group)
Number of subjects: 66
Study: 19399946

Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP, PetCO2, and clinical assessment
Number of subjects: 441

Group type: COMPARATOR
Intervention: NT-proBNP alone
Number of subjects: 441

Group type: COMPARATOR
Intervention: NT-proBNP in combination with clinical assessment
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: NT-proBNP > or = 2000 pg/mL and PetCO2 < or = 4 kPa
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Previous history of COPD/asthma in acute HF dyspneic patients
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Previous history of HF in COPD/asthma dyspneic patients
Number of subjects: 441
Study: 19400961

Group type: EXPERIMENTAL
Intervention: Proactive telephone support for smoking cessation
Number of subjects: 2576

Group type: COMPARATOR
Intervention: Reactive telephone support for smoking cessation
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) offered in addition to telephone counselling
Number of subjects: 2576

Group type: COMPARATOR
Intervention: No offer of Nicotine Replacement Therapy (NRT)
Number of subjects: 2576
Study: 19402886

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) at a dosage of 0.625 mg/d for 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 100
Study: 19403641

Group type: EXPERIMENTAL
Intervention: High-fructose diet (3.5 g x kg FFM(-1) x d(-1), +35% energy intake)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 24
Study: 19404953

Group type: EXPERIMENTAL
Intervention: Azathioprine treatment
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Moderate dosage of prednisone (0.15-0.4 mg/kg/day)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High-dose prednisone
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a) level
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Increased creatinine clearance
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 221
Study: 19406289

Group type: EXPERIMENTAL
Intervention: Lower thoracic spinal cord stimulation (SCS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined stimulation of any 2 leads of SCS
Number of subjects: 9
Study: 19406290

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) performed at home by subjects or caregivers
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 9
Study: 19406978

Group type: EXPERIMENTAL
Intervention: Homozygous LL patients
Number of subjects: 260
Study: 19407319

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19407658

Group type: EXPERIMENTAL
Intervention: Single-pill amlodipine/atorvastatin (5/10-10/80 mg) with lifestyle modification
Number of subjects: 2245

Group type: EXPERIMENTAL
Intervention: Single-pill amlodipine/atorvastatin
Number of subjects: 2245
Study: 19411292

Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 34
Study: 19411368

Group type: EXPERIMENTAL
Intervention: Major depression group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 30
Study: 19411393

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (initially) then switched to Etanercept
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 81
Study: 19412327

Group type: EXPERIMENTAL
Intervention: Mobile diary
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 12
Study: 19415121

Group type: EXPERIMENTAL
Intervention: Customized therapy based on BRCA1 mRNA levels
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Chemotherapy with low BRCA1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Chemotherapy with intermediate BRCA1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Chemotherapy with high BRCA1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients with low BRCA1 and low RAP80
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: RAP80 expression
Number of subjects: 123
Study: 19416525

Group type: EXPERIMENTAL
Intervention: Single Tailored (ST) packet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) packet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple Re-Tailored (MRT) packets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontailored (NT) comparison group
Number of subjects: 0
Study: 19418039

Group type: EXPERIMENTAL
Intervention: Immunosuppression and euglycaemia from beta cell allograft
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Prolonged euglycaemia plus anti-rejection immunosuppressive therapy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Selective venous sampling
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Arginine stimulation tests
Number of subjects: 141
Study: 19419474

Group type: EXPERIMENTAL
Intervention: Topical imiquimod applied three to seven times per week for 16 weeks
Number of subjects: 16
Study: 19419546

Group type: EXPERIMENTAL
Intervention: COPD disease risk index assessment
Number of subjects: 0
Study: 19419611

Group type: EXPERIMENTAL
Intervention: Transantral balloon dilation under local anesthesia
Number of subjects: 30
Study: 19419830

Group type: EXPERIMENTAL
Intervention: Fast dynamic gadolinium-enhanced MR imaging combined with MR colonography
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MR colonography
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fast dynamic gadolinium-enhanced MR imaging
Number of subjects: 14
Study: 19421322

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 13 weeks
Number of subjects: 10
Study: 19422756

Group type: EXPERIMENTAL
Intervention: Targeted acupuncture (points specific to symptoms) for hypomania over 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Targeted acupuncture for depression over 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Acupuncture points off the acupuncture meridian for hypomania over 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Acupuncture for nonpsychiatric health concerns for depression over 8 weeks
Number of subjects: 46
Study: 19423725

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) and antithymocyte globulin (ATG)
Number of subjects: 111
Study: 19426530

Group type: EXPERIMENTAL
Intervention: Bluetooth enabled blood glucose monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes intensification management program by the Home Care team supported by Bluetooth enabled glucose meters
Number of subjects: 0
Study: 19426959

Group type: EXPERIMENTAL
Intervention: AcrySof Natural IOLs
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clear IOLs
Number of subjects: 58
Study: 19427025

Group type: EXPERIMENTAL
Intervention: 2nd-line topotecan-based chemotherapy
Number of subjects: 525
Study: 19427617

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 631

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 631
Study: 19427760

Group type: EXPERIMENTAL
Intervention: Citrate-based substitution fluid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bicarbonate-based CVVH
Number of subjects: 29
Study: 19427992

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 96
Study: 19432972

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 18
Study: 19433856

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 11
Study: 19434385

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin (UUI subgroup)
Number of subjects: 0
Study: 19439093

Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection (IV) at 5 dose levels (50, 100, 200, 400, and 600 mg/m2) on days 1 to 5 of a 14-day cycle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection (IV) at 600 mg/m2 on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection
Number of subjects: 54
Study: 19440083

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d (smokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d (smokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (smokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d (nonsmokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d (nonsmokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (nonsmokers)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (African Americans)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (Whites)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Olanzapine (overall)
Number of subjects: 380
Study: 19440247

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 42
Study: 19441600

Group type: EXPERIMENTAL
Intervention: Asthma Self-Management Questionnaire (ASMQ)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Asthma Self-Management Questionnaire (ASMQ) after 12 months
Number of subjects: 256
Study: 19442962

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 2
Study: 19443656

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T lymphocytes (CTLs) expanded from CB T cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTLs from CB targeting EBV, CMV, and Adv.
Number of subjects: 0
Study: 19443658

Group type: EXPERIMENTAL
Intervention: CALM-AF10 fusion protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukemia patients harboring CALM-AF10 fusion
Number of subjects: 0
Study: 19445710

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thyroid fine-needle aspiration biopsies (USG-FNA)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Palpation-guided thyroid fine-needle aspiration biopsies (P-FNA)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison
Number of subjects: 268
Study: 19446146

Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3, 1.0, 3.0, or 9.0 mg/kg administered intravenously
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3, 1.0, 3.0, or 9.0 mg/kg administered subcutaneously
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MEDI-528 administered intravenously
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MEDI-528 administered subcutaneously
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MEDI-528 3.0 mg/kg administered intravenously
Number of subjects: 53
Study: 19447923

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 224
Study: 19448188

Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of frontostriatal circuits in children with Tourette's syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of frontostriatal circuits in children with OCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of adolescents and adults with anorexia nervosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of adolescents and adults with bulimia nervosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impaired capacity for self-regulatory control
Number of subjects: 0
Study: 19450141

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program for 6 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 165
Study: 19451441

Group type: EXPERIMENTAL
Intervention: Veltuzumab (80 to 750 mg/m², four once-weekly doses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veltuzumab in follicular lymphoma
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veltuzumab in marginal zone lymphoma
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veltuzumab in diffuse large B-cell lymphoma
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veltuzumab pharmacodynamics
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veltuzumab pharmacokinetics
Number of subjects: 82
Study: 19453788

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 9265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9265
Study: 19454532

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (0.3 mg/kg/day for 4 days)
Number of subjects: 13
Study: 19455012

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-infected participants vs. controls
Number of subjects: 0
Study: 19456296

Group type: EXPERIMENTAL
Intervention: Audit program implemented after February 16, 2007
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (before audit program)
Number of subjects: 180
Study: 19457240

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA) administered within 24 hours of first sepsis-induced organ dysfunction
Number of subjects: 305

Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated) (DrotAA) administered after 24 hours of first sepsis-induced organ dysfunction
Number of subjects: 305
Study: 19457245

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with CPT-11, 5-FU, and LV for 12 weeks (preoperative phase)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postoperative treatment with the same regimen (CPT-11, 5-FU, and LV) for 12 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 35